Journal of Clinical Oncology, Vol 16, 19-26, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

JH Glick, ML Young, D Harrington, RL Schilsky, T Beck, R Neiman, RI Fisher, BA Peterson and MM Oken
University of Pennsylvania Cancer Center, Philadelphia 19104-4283, USA. glickjh@mail.med.upenn.edu

PURPOSE: To compare the efficacy of sequential mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) followed by doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) versus the MOPP/ABV hybrid regimen in advanced-stage Hodgkin's disease. PATIENTS AND METHODS: A total of 737 patients with previously untreated stages III2A, IIIB, IVA, or IVB Hodgkin's disease and patients in first relapse after radiotherapy were prospectively randomized to sequential MOPP-ABV or MOPP/ABV hybrid. Of 691 eligible patients, 344 received the sequential regimen and 347 received the hybrid. RESULTS: The overall response rate was 95%, with complete responses (CRs) in 79%: 83% on the MOPP/ABV hybrid and 75% on the sequential MOPP-ABVD arm (P = .02). With a median follow-up time of 7.3 years, the 8-year failure-free survival (FFS) rates were 64% for MOPP/ABV hybrid and 54% far sequential MOPP- ABVD (P = .01; 0.69 relative risk of failure, comparing MOPP/ABV hybrid v MOPP-ABVD). The 8-year overall survival rate was significantly better for the MOPP/ABV hybrid (79%) as compared with sequential MOPP-ABVD (71%) (P = .02; relative risk, 0.65). MOPP/ABV hybrid had significantly more life-threatening or fatal neutropenia and pulmonary toxicity than the sequential MOPP-ABVD arm, which was associated with significantly greater thrombocytopenia. Nine cases of acute myelogenous leukemia or myelodysplasia were reported on the sequential regimen as compared with only one on the hybrid (P = .01). CONCLUSION: MOPP/ABV hybrid chemotherapy was significantly more effective than sequential MOPP- ABVD. FFS and overall survival were significantly improved on the hybrid arm, which was also associated with a lower incidence of acute leukemia or myelodysplasia.

This article has been cited by other articles:

				B. D. Cheson and G. P. Canellos The cancer and leukemia group B lymphoma committee. Clin. Cancer Res., June 1, 2006; 12(11): 3572s - 3575s. [Abstract] [Full Text] [PDF]

				P. G. Gobbi, C. Broglia, A. Levis, A. La Sala, F. Valentino, T. Chisesi, S. Sacchi, F. Corbella, L. Cavanna, E. Iannitto, et al. MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin's Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors Clin. Cancer Res., January 15, 2006; 12(2): 529 - 535. [Abstract] [Full Text] [PDF]

				P. G. Gobbi, A. Levis, T. Chisesi, C. Broglia, U. Vitolo, C. Stelitano, V. Pavone, L. Cavanna, G. Santini, F. Merli, et al. ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi J. Clin. Oncol., December 20, 2005; 23(36): 9198 - 9207. [Abstract] [Full Text] [PDF]

				V. Ballova, J.-U. Ruffer, H. Haverkamp, B. Pfistner, H. K. Muller-Hermelink, E. Duhmke, P. Worst, M. Wilhelmy, R. Naumann, M. Hentrich, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly) Ann. Onc., January 1, 2005; 16(1): 124 - 131. [Abstract] [Full Text] [PDF]

				B. M.P. Aleman, J. M.M. Raemaekers, U. Tirelli, R. Bortolus, M. B. van 't Veer, M. L.M. Lybeert, J. J. Keuning, P. Carde, T. Girinsky, R. W.M. van der Maazen, et al. Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma N. Engl. J. Med., June 12, 2003; 348(24): 2396 - 2406. [Abstract] [Full Text] [PDF]

				M. Sieber, H. Bredenfeld, A. Josting, T. Reineke, U. Rueffer, T. Koch, R. Naumann, F. Boissevain, P. Koch, P. Worst, et al. 14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin's Lymphoma: Results of a Pilot Study of the German Hodgkin's Lymphoma Study Group J. Clin. Oncol., May 1, 2003; 21(9): 1734 - 1739. [Abstract] [Full Text] [PDF]

				V. Diehl Advanced Hodgkin's Disease: ABVD Is Better, Yet Is Not Good Enough! J. Clin. Oncol., February 15, 2003; 21(4): 583 - 585. [Full Text] [PDF]

				D. B. Duggan, G. R. Petroni, J. L. Johnson, J. H. Glick, R. I. Fisher, J. M. Connors, G. P. Canellos, and B. A. Peterson Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin's Disease: Report of an Intergroup Trial J. Clin. Oncol., February 15, 2003; 21(4): 607 - 614. [Abstract] [Full Text] [PDF]

				G. P. Canellos, J. Gollub, D. Neuberg, P. Mauch, and L. N. Shulman Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up Ann. Onc., February 1, 2003; 14(2): 268 - 272. [Abstract] [Full Text] [PDF]

				V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease Hematology, January 1, 2003; 2003(1): 225 - 247. [Abstract] [Full Text] [PDF]

				M. Sieber, H. Tesch, B. Pfistner, U. Rueffer, B. Lathan, O. Brosteanu, U. Paulus, T. Koch, M. Pfreundschuh, M. Loeffler, et al. Rapidly Alternating COPP/ABV/IMEP Is Not Superior to Conventional Alternating COPP/ABVD in Combination With Extended-Field Radiotherapy in Intermediate-Stage Hodgkin's Lymphoma: Final Results of the German Hodgkin's Lymphoma Study Group Trial HD5 J. Clin. Oncol., January 15, 2002; 20(2): 476 - 484. [Abstract] [Full Text] [PDF]

				J. M. Connors, E. M. Noordijk, and S. J. Horning Hodgkin's Lymphoma: Basing the Treatment on the Evidence Hematology, January 1, 2001; 2001(1): 178 - 193. [Abstract] [Full Text] [PDF]

				S. J. Horning, J. Williams, N. L. Bartlett, J. M. Bennett, R. T. Hoppe, D. Neuberg, and P. Cassileth Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin’s Disease: Eastern Cooperative Oncology Group Pilot Study E1492 J. Clin. Oncol., March 1, 2000; 18(5): 972 - 972. [Abstract] [Full Text] [PDF]

				A. C. Aisenberg Problems in Hodgkin's Disease Management Blood, February 1, 1999; 93(3): 761 - 779. [Full Text] [PDF]

				D. Hasenclever, V. Diehl, J. O. Armitage, D. Assouline, M. Bjorkholm, E. Brusamolino, G. P. Canellos, P. Carde, D. Crowther, D. Cunningham, et al. A Prognostic Score for Advanced Hodgkin's Disease N. Engl. J. Med., November 19, 1998; 339(21): 1506 - 1514. [Abstract] [Full Text] [PDF]